Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02279173
Registration number
NCT02279173
Ethics application status
Date submitted
1/10/2014
Date registered
30/10/2014
Date last updated
23/06/2022
Titles & IDs
Public title
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Query!
Scientific title
A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Query!
Secondary ID [1]
0
0
2011-005019-96
Query!
Secondary ID [2]
0
0
20101221
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Immune Thrombocytopenia
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Romiplostim
Experimental: Romiplostim - Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count = 50 x 10?/L.
Treatment: Drugs: Romiplostim
Romiplostim subcutaneous weekly injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Time With a Platelet Response During the First 6 Months of Treatment
Query!
Assessment method [1]
0
0
Platelet response was defined as a platelet count of = 50 x 10?/L with no rescue medication use for ITP in the past 4 weeks.
Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response during the first 6 months was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.
Query!
Timepoint [1]
0
0
Week 2 to Month 6, platelet response was assessed every week.
Query!
Primary outcome [2]
0
0
Percentage of Participants Who Developed Collagen After Exposure to Romiplostim
Query!
Assessment method [2]
0
0
The percentage of participants who developed collagen as evidenced by trichrome staining, defined as a Grade 4 on the modified Bauermeister grading scale:
Grade 0: No reticulin fibers demonstrable
Grade 1: Occasional fine individual fibers and foci of a fine fiber network
Grade 2: Fine fiber network throughout most of the section; no coarse fibers
Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining)
Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)
Query!
Timepoint [2]
0
0
Year 1 (Cohort 1) and year 2 (Cohort 2)
Query!
Primary outcome [3]
0
0
Percentage of Participants With Increased Modified Bauermeister Grade
Query!
Assessment method [3]
0
0
The percentage of participants with an increased modified Bauermeister grade defined as an increase by = 2 severity grades or an increase to grade 4 (i.e., grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister grading scale:
Grade 0: No reticulin fibers demonstrable
Grade 1: Occasional fine individual fibers and foci of a fine fiber network
Grade 2: Fine fiber network throughout most of the section; no coarse fibers
Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining)
Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)
Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.
Query!
Timepoint [3]
0
0
Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)
Query!
Primary outcome [4]
0
0
Percentage of Participants Who Developed Bone Marrow Abnormalities
Query!
Assessment method [4]
0
0
The percentage of participants with bone marrow abnormalities (eg, myelodysplastic syndrome, monosomy 7) based on analysis of bone marrow biopsy and aspirate samples using cytogenetics and fluorescence in situ hybridization.
Query!
Timepoint [4]
0
0
Year 1 (Cohort 1) and year 2 (Cohort 2)
Query!
Secondary outcome [1]
0
0
Percentage of Time With a Platelet Response During the Overall Treatment Period
Query!
Assessment method [1]
0
0
Platelet response was defined as a platelet count of = 50 x 10?/L with no rescue medication use in the past 4 weeks.
Monthly platelet response was calculated based on the median platelet count during each month. For each participant, the percentage of time with platelet response was calculated as the number of months a platelet response was observed divided by the total number of months response was assessed.
Query!
Timepoint [1]
0
0
From week 2 to the end of the treatment period, 36 months
Query!
Secondary outcome [2]
0
0
Percentage of Time With an Increase in Platelet Count = 20 x 10? Cells/L Above Baseline
Query!
Assessment method [2]
0
0
The percentage of time with an increase in platelet count = 20 x 10? cells/L above baseline from week 2 until the end of the treatment period without rescue medication use within the past 4 weeks.
For each participant, the percentage of time with an increase in platelet count = 20 x10? cells/L above baseline was calculated as the number of months the median platelet count was = 20 x10? cells/L above baseline divided by the total number of months assessed.
Query!
Timepoint [2]
0
0
Baseline and from week 2 to month 36
Query!
Secondary outcome [3]
0
0
Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period
Query!
Assessment method [3]
0
0
Rescue medication is defined as any medication or transfusion, other than romiplostim and excluded medications, that is administered after enrollment to the participant with the intent of raising platelet counts or to prevent bleeding and includes concomitant medications for ITP in which the dose and/or schedule was increased. Permitted rescue medications included the following:
corticosteroids
platelet transfusions
Intravenous immunoglobulin (IVIG)
azathioprine
anti-D immunoglobulin
danazol
Query!
Timepoint [3]
0
0
From first dose of romiplostim to the end of the treatment period, 36 months
Query!
Secondary outcome [4]
0
0
Number of Participants Who Developed Anti-Romiplostim or Anti-Thrombopoietin Neutralizing Antibodies
Query!
Assessment method [4]
0
0
Blood samples were first tested for the presence of binding antibodies to romiplostim or the peptide portion of romiplostim, and to endogenous thrombopoietin (eTPO). Samples testing positive for binding antibodies were then tested for neutralizing antibodies by assessing their ability to neutralize romiplostim and/or eTPO in a cell-based bioassay.
Participants who developed neutralizing antibodies are those who had a postbaseline positive result with a negative or no result at baseline. Transient is defined as a negative result at the participant's last time point tested within the study period.
Query!
Timepoint [4]
0
0
Week 12, week 52 and every 24 weeks thereafter up to month 36
Query!
Secondary outcome [5]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [5]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant, which does not necessarily have a causal relationship with study treatment.
A serious adverse event (SAE) was defined as an AE that met at least 1 of the following criteria:
fatal
life threatening
required in-patient hospitalization or prolongation of existing hospitalization
resulted in persistent or significant disability/incapacity
congenital anomaly/birth defect
other medically important serious event Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = mild AE; Grade 2 = moderate AE; Grade 3 = severe AE; Grade 4 = life-threatening or disabling; Grade 5 = death related to AE.
Query!
Timepoint [5]
0
0
SAEs were collected from Screening through end-of-study follow-up (up to 38 months). Nonserious AEs were collected from first to last dose of study drug during the treatment period (up to 36 months).
Query!
Secondary outcome [6]
0
0
Percentage of Participants Who Developed Increased Reticulin
Query!
Assessment method [6]
0
0
The percentage of participants with increased reticulin as evidenced by silver staining and defined as any increase from baseline in the modified Bauermeister grade:
Grade 0: No reticulin fibers demonstrable
Grade 1: Occasional fine individual fibers and foci of a fine fiber network
Grade 2: Fine fiber network throughout most of the section; no coarse fibers
Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining)
Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)
Participants without an evaluable baseline result were assumed to have a baseline modified Bauermeister score of 0.
Query!
Timepoint [6]
0
0
Baseline, year 1 (Cohort 1) and year 2 (Cohort 2)
Query!
Eligibility
Key inclusion criteria
- Diagnosis of primary ITP according to The American Society of Hematology (ASH)
Guidelines at least 6 months before screening, regardless of splenectomy status
- Age = 1 year and < 18 years of age
- Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible
for other therapies. Examples of prior therapy include: corticosteroids, intravenous
Immunoglobulin (IVIG), anti-D immunoglobulin, platelet transfusions.
- Platelet count = 30 x10^9/L or is experiencing uncontrolled bleeding
- Has provided informed consent before any study-specific procedure;
- Adequate hematologic, renal, and liver function during screening:
- Hemoglobin > 10.0 g/dL
- Serum creatinine = 1.5 x the upper limit of normal (ULN)
- Total serum bilirubin = 1.5 x the ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x the
ULN
- For the EU, Switzerland and Turkey protocol supplement, subject must agree to a
scheduled bone marrow biopsy and aspirate at Year 1 or Year 2 following romiplostim
treatment and any unscheduled biopsies if clinically indicated
- For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2,
or 3 according to the modified Bauermeister grading scale, as assessed by central
laboratory from a bone marrow biopsy performed within 1 year prior to planned first
dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate
prior to planned first dose of romiplostim
Query!
Minimum age
1
Year
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other
than those typical of ITP must be approved by Amgen before a subject may be enrolled)
- Prior bone marrow transplant or peripheral blood progenitor cell transplant
- Active or prior malignancy except non-melanoma skin cancers within the last 5 years
- History of myelodysplastic syndrome
- History of bleeding diathesis
- History of congenital thrombocytopenia
- History of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV)
- History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia
- History of antiphospholipid antibody syndrome or known positive for lupus
anticoagulant
- History of disseminated intravascular coagulation, hemolytic uremic syndrome, or
thrombotic thrombocytopenic purpura
- History of venous thromboembolism or thrombotic events
- Previous use of romiplostim or previous use of eltrombopag within 4 weeks of
enrollment
- Previous use of pegylated recombinant human megakaryocyte growth and development
factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other platelet
producing agent
- Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or
anticipated use at any time during the study
- Splenectomy within 4 weeks of the screening visit
- Alkylating agents within 8 weeks before the screening visit or anticipated use during
the time of the proposed study
- Vaccinations known to decrease platelet counts within 8 weeks before the screening
visit
- Currently enrolled in another investigational device or drug study, or less than 30
days since ending investigational study
- Will have investigational procedures while enrolled on study
- Female subject of child bearing potential (defined as having first menses) not willing
to use, in combination with her partner highly effective methods of birth control
during treatment and for 1 month after the end of treatment
- Subject is pregnant or breast feeding, or might become pregnant within 1 month after
the end of treatment
- Subject has known hypersensitivity to any recombinant Escherichia coli derived product
(eg, Infergen®, Neupogen®, somatropin, and Actimmune®)
- Has previously enrolled into this study
- Will not be available for protocol-required study visits or procedures, to the best of
the subject's and investigator's knowledge
- Any kind of disorder that, may compromise the subject to give written informed consent
and/or to comply with all required study procedures
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/08/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
203
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Randwick
Query!
Recruitment hospital [2]
0
0
Research Site - South Brisbane
Query!
Recruitment hospital [3]
0
0
Research Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nevada
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brussels
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Bruxelles
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Gent
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Leuven
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Liege
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Pará
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
São Paulo
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Olomouc
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Ostrava-Poruba
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Praha 5
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Montpellier cedex 05
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Nice Cedex 3
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Vandoeuvre les Nancy
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Budapest
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Debrecen
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Szeged
Query!
Country [32]
0
0
Israel
Query!
State/province [32]
0
0
Beer Sheva
Query!
Country [33]
0
0
Israel
Query!
State/province [33]
0
0
Haifa
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Jerusalem
Query!
Country [35]
0
0
Israel
Query!
State/province [35]
0
0
Petach Tikvah
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Tel Aviv
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Tel Hashomer
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Nuevo León
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Bydgoszcz
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Lodz
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Olsztyn
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Zabrze
Query!
Country [43]
0
0
Russian Federation
Query!
State/province [43]
0
0
Krasnodar
Query!
Country [44]
0
0
Russian Federation
Query!
State/province [44]
0
0
Moscow
Query!
Country [45]
0
0
Russian Federation
Query!
State/province [45]
0
0
Saint-Petersburg
Query!
Country [46]
0
0
Russian Federation
Query!
State/province [46]
0
0
Saratov
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
Volgograd
Query!
Country [48]
0
0
South Africa
Query!
State/province [48]
0
0
Gauteng
Query!
Country [49]
0
0
South Africa
Query!
State/province [49]
0
0
KwaZulu-Natal
Query!
Country [50]
0
0
South Africa
Query!
State/province [50]
0
0
Western Cape
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Cataluña
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Comunidad Valenciana
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Madrid
Query!
Country [54]
0
0
Switzerland
Query!
State/province [54]
0
0
Basel
Query!
Country [55]
0
0
Switzerland
Query!
State/province [55]
0
0
St. Gallen
Query!
Country [56]
0
0
Switzerland
Query!
State/province [56]
0
0
Zuerich
Query!
Country [57]
0
0
Turkey
Query!
State/province [57]
0
0
Adana
Query!
Country [58]
0
0
Turkey
Query!
State/province [58]
0
0
Antalya
Query!
Country [59]
0
0
Turkey
Query!
State/province [59]
0
0
Izmir
Query!
Country [60]
0
0
United Kingdom
Query!
State/province [60]
0
0
Birmingham
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
Edinburgh
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
London
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 3b single arm, open label, multicenter study describing the percentage of
time pediatric participants with ITP have a platelet response while receiving romiplostim,
defined as a platelet count = 50 x 10^9/L in the absence of ITP rescue medications for the
past 4 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02279173
Query!
Trial related presentations / publications
Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Pediatr Blood Cancer. 2020 Nov;67(11):e28630. doi: 10.1002/pbc.28630. Epub 2020 Sep 9.
Grainger J, Bussel J, Tarantino M, Cooper N, Beam D, Despotovic J, Maschan A, Wang K, Eisen M, Bowers C. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia. Blood Adv. 2023 Feb 14;7(3):396-405. doi: 10.1182/bloodadvances.2021006014.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02279173
Download to PDF